0001140361-16-083653.txt : 20161026 0001140361-16-083653.hdr.sgml : 20161026 20161026164127 ACCESSION NUMBER: 0001140361-16-083653 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161024 FILED AS OF DATE: 20161026 DATE AS OF CHANGE: 20161026 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Raptor Pharmaceutical Corp CENTRAL INDEX KEY: 0001070698 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 860883978 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7 HAMILTON LANDING STREET 2: SUITE 100 CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 415-408-6200 MAIL ADDRESS: STREET 1: 7 HAMILTON LANDING STREET 2: SUITE 100 CITY: NOVATO STATE: CA ZIP: 94949 FORMER COMPANY: FORMER CONFORMED NAME: Raptor Pharmaceutical Corp. DATE OF NAME CHANGE: 20090929 FORMER COMPANY: FORMER CONFORMED NAME: TorreyPines Therapeutics, Inc. DATE OF NAME CHANGE: 20061003 FORMER COMPANY: FORMER CONFORMED NAME: AXONYX INC DATE OF NAME CHANGE: 19990303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Happel David CENTRAL INDEX KEY: 0001623567 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-25571 FILM NUMBER: 161953067 MAIL ADDRESS: STREET 1: 7 HAMILTON LANDING STREET 2: SUITE 100 CITY: NOVATO STATE: CA ZIP: 94949 4 1 doc1.xml FORM 4 X0306 4 2016-10-24 1 0001070698 Raptor Pharmaceutical Corp RPTP 0001623567 Happel David C/O RAPTOR PHARMACEUTICAL CORP. 7 HAMILTON LANDING, SUITE 100 NOVATO CA 94949 0 1 0 0 Chief Commercial Officer Common Stock 2016-10-24 4 U 0 8934 9.00 D 28939 D Common Stock 2016-10-25 4 D 0 28939 9.00 D 0 D Stock Option (right to buy) 3.74 2016-10-25 4 D 0 93784 D 2026-02-09 Common Stock 93784 0 D Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes. Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. /s/ Sally Brammell, as Attorney-in-Fact 2016-10-25